ProBio signs global antibody licensing deal with AbTis
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
Oyster Therapeutics, formerly known as Kesmalea Therapeutics, has closed a $60m Series A-2 financing round to advance targeted protein degraders for neurodegenerative diseases including Alzheimer’s.
Delix Therapeutics has secured $100m in an oversubscribed Series C financing round to fund the development of zalsupindole (DLX001), an orally bioavailable neuroplastogen.
Charles River Laboratories International (CRL) has signed definitive agreements to acquire Frontage Holdings’ bioanalysis and drug metabolism and pharmacokinetics (DMPK) operations in Pennsylvania, US for roughly $470m in cash.
Enthorin Therapeutics has signed an option-to-license agreement with Rumi Therapeutics to advance ENT-7340 for Fragile X syndrome (FXS), as well as other intellectual and developmental disabilities.
AI Proteins has signed a research collaboration and licence agreement with Astellas Pharma’s affiliate Astellas Innovation Management for discovering and developing miniprotein therapeutics.
Sanofi has signed a global licensing and strategic collaboration agreement with UK-based biotechnology company ScionxBio to develop long-acting messenger ribonucleic acid (mRNA) therapies using the TERA platform.
Transcripta Bio has entered into a research collaboration and licensing agreement with Mayo Clinic to identify potential treatments and therapeutic targets for amyotrophic lateral sclerosis (ALS).
Pfizer and Enodia Therapeutics have announced a research collaboration and licensing deal potentially worth over $500m to discover and develop Sec61 inhibitors.
Southern Research has secured an $8m grant from the US National Institutes of Health (NIH) to establish a national shared-use biomedical facility, the Translational Hub for Research, Innovation, Validation, and Excellence (THRIVE).